ASH 2022 Conference Coverage

 

ASH 2022 Conference Coverage
J

ASH 2022 on Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia

By ASH 2022 Conference Coverage FEATURING Jorge Castillo
By ASH 2022 Conference Coverage FEATURING Jorge Castillo
59 views
December 22, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
Lymphoma
05:34
ASH 2022 Conference Coverage

ASH 2022 Patient Reports Outcomes & Health-Related Quality of Li…

Feat. Y. Linhares
05:08
ASH 2022 Conference Coverage

ASH 2022 Results From the Phase 2 OUTREACH Study: Lisocabtagene Mara…

Feat. Y. Linhares
07:06
ASH 2022 Conference Coverage

ASH 2022 Phase 3 ZUMA-7 Study: Outcomes of Subsequent Anti-Lymphoma …

Feat. A. Ghobadi
06:31
ASH 2022 Conference Coverage

ASH 2022 Results From a Prespecified Analysis of the Pivotal Phase I…

Feat. D. Jagadeesh
12:39
ASH 2022 Conference Coverage

ASH 2022 Five-Year Survival Results From REMoDL-B: Outcomes in DLBCL…

Feat. A. Davies
08:04
ASH 2022 Conference Coverage

ASH 2022 Results from BRUIN: A Phase 1/2 Study of Pirtobrutinib, a H…

Feat. N. Shah
08:54
ASH 2022 Conference Coverage

ECOG-ACRIN E1411: A Randomized Phase 2 Trial of First-Line Bendamust…

Feat. M. Smith
04:07
ASH 2022 Conference Coverage

ASH 2022 Anti-CD19 CAR T-Cell Therapy for Patients With Richter Synd…

Feat. R. Guieze
10:17
ASH 2022 Conference Coverage

ASH 2022 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenali…

Feat. C. Melani
27:09
ASH 2022 Conference Coverage

ASH 2022: What Is Complete HLA Match in 2022?

Feat. S. Spellman
12:50
ASH 2022 Conference Coverage

ASH 2022 on Ibrutinib and Venetoclax in Previously Untreated Waldens…

Feat. J. Castillo
07:49
ASH 2022 Conference Coverage

ASH 2022 High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS In…

Feat. N. Epperla
06:12
ASH 2022 Conference Coverage

ASH 2022 Phase 1b/2a Study Results From Dose-Escalation: AZD4573 (CD…

Feat. P. Strati
14:28
ASH 2022 Conference Coverage

ASH 2022 CNS Prophylaxis in Aggressive B-Cell Lymphoma

Feat. K. Cwynarski
06:35
ASH 2022 Conference Coverage

Results From a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-…

Feat. N. Shah
10:36
ASH 2022 Conference Coverage

The CAR-HEMATOTOX Score Identifies Patients at High Risk for Hematol…

Feat. K. Rejeski
05:04
ASH 2022 Conference Coverage

ASH 2022 Phase III SUNMO Trial: Evaluating the Efficacy & Safety…

Feat. J. Westin
08:34
ASH 2022 Conference Coverage

ASH 2022: Zanubrutinib in Acalabrutinib-Intolerant Patients With B-C…

Feat. M. Shadman
08:02
ASH 2022 Conference Coverage

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…

Feat. S. Holtan
08:15
ASH 2022 Conference Coverage

ASH 2022: Glofitamab Monotherapy Induces High Complete Response Rate…

Feat. T. Phillips
06:01
ASH 2022 Conference Coverage

ASH 2022 Outcomes of R/R Double Hit Lymphoma: A Multicenter Observat…

Feat. S. Desai
12:52
ASH 2022 Conference Coverage

ASH 2022 on the Phase Ib/II Study of Polatuzumab Vedotin + Obinutuzu…

Feat. C. Diefenbach
05:55
ASH 2022 Conference Coverage

ASH 2022 Phase 3 ZUMA-7 Trial Updates: Association of Metabolic Tumo…

Feat. F. Locke
07:02
ASH 2022 Conference Coverage

ASH 2022 Results of the Phase II Radvax Trial: Low-Dose RT With Nivo…

Feat. M. LaRiviere